Conatus Pharmaceuticals Inc (CNAT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Conatus Pharmaceuticals Inc (CNAT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7972
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Conatus Pharmaceuticals Inc (Conatus) is a biotechnology company that develops and commercializes novel medicines for the treatment of liver diseases. The company’s lead pipeline candidate includes emricasan, an orally active pan-caspase protease inhibitor which is designed to reduce the activity of human caspases and is intended for the treatment of various indications such as post-orthotopic liver transplant, nonalcoholic steatohepatitis (NASH) cirrhosis and NASH fibrosis. Its other preclinical product candidates include IDN-7314, a pan-caspase inhibitor intended for the treatment of primary sclerosing cholangitis; and others. Conatus is headquartered in San Diego, California, the US.

Conatus Pharmaceuticals Inc (CNAT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Conatus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
IDUN Pharma Raises USD1.1 Million in Financing 12
IDUN Pharma Raises Additional USD0.2 Million in Financing 13
Idun Pharma Raises USD0.23 Millin in Extended Venture Financing 14
Idun Pharma Raises US$0.3 Million In Venture Financing 15
Partnerships 16
Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 16
Licensing Agreements 18
Novartis Pharma Exercises Option for Licensing Agreement with Conatus Pharma 18
Conatus Pharma Enters into Sub-Licensing Agreement with Idun Pharma 19
Equity Offering 20
Conatus Pharma to Raise up to USD35 Million in Public Offering of Shares 20
Conatus Pharma Raises USD32.89 Million in Public Offering of Shares 21
Conatus Pharma Raises USD23 Million in Public Offering of Shares 23
Conatus Pharmaceuticals Completes IPO Of Shares For US$66 Million 25
Debt Offering 27
Conatus Pharmaceuticals Raises USD1 Million in Private Placement of Notes 27
Conatus Pharmaceuticals Inc – Key Competitors 28
Conatus Pharmaceuticals Inc – Key Employees 29
Conatus Pharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 01, 2018: Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates 31
May 02, 2018: Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates 33
Mar 07, 2018: Conatus Pharmaceuticals Reports 2017 Financial Results and Program Updates 34
Nov 01, 2017: Conatus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Program Updates 36
Aug 02, 2017: Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates 38
May 04, 2017: Conatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates 40
Mar 15, 2017: Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates 41
Corporate Communications 43
Aug 31, 2017: Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer 43
Feb 07, 2017: Conatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member 44
Feb 02, 2017: Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management 45
Product Approvals 46
Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Conatus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Conatus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
IDUN Pharma Raises USD1.1 Million in Financing 12
IDUN Pharma Raises Additional USD0.2 Million in Financing 13
Idun Pharma Raises USD0.23 Millin in Extended Venture Financing 14
Idun Pharma Raises US$0.3 Million In Venture Financing 15
Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 16
Novartis Pharma Exercises Option for Licensing Agreement with Conatus Pharma 18
Conatus Pharma Enters into Sub-Licensing Agreement with Idun Pharma 19
Conatus Pharma to Raise up to USD35 Million in Public Offering of Shares 20
Conatus Pharma Raises USD32.89 Million in Public Offering of Shares 21
Conatus Pharma Raises USD23 Million in Public Offering of Shares 23
Conatus Pharmaceuticals Completes IPO Of Shares For US$66 Million 25
Conatus Pharmaceuticals Raises USD1 Million in Private Placement of Notes 27
Conatus Pharmaceuticals Inc, Key Competitors 28
Conatus Pharmaceuticals Inc, Key Employees 29
Conatus Pharmaceuticals Inc, Subsidiaries 30

List of Figures
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Conatus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Conatus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Conatus Pharmaceuticals Inc (CNAT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Senzime AB (SEZI):企業の財務・戦略的SWOT分析
    Summary Senzime AB (Senzime) is a medical device company that develops patient-oriented monitoring systems. The company's product include TetraGraph monitor, CliniSenz analyzer, and Onzurf probe. Its TetraGraph monitor stimulates, measures, analyzes and displays muscle function in surgical patients …
  • PT. Matahari Putra Prima Tbk (MPPA):企業の財務・戦略的SWOT分析
    PT. Matahari Putra Prima Tbk (MPPA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Enviva Partners LP (EVA):企業の財務・戦略的SWOT分析
    Enviva Partners LP (EVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tong Ren Tang Technologies Co Ltd (1666):企業の財務・戦略的SWOT分析
    Summary Tong Ren Tang Technologies Co Ltd (TRTT), a subsidiary of Beijing Tong Ren Tang Co Ltd is a pharmaceutical company that manufactures and supplies Chinese medicines. The company’s products comprise Chinese medicine, healthy food and maier hai cosmetics. It offers products in the forms of pill …
  • Semtech Corp (SMTC):企業の財務・戦略的SWOT分析
    Summary Semtech Corp (Semtech) is a supplier of analog and mixed-signal semiconductor products. The company provides products such as isolated power switches, UHD-SDI gearbox, wireless charging ICs, battery chargers, cable drivers, capacitive touch controllers, charge pump and current sink led drive …
  • Shinsegae Food Co., Ltd.:企業の戦略・SWOT・財務情報
    Shinsegae Food Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shinsegae Food Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Calypso Biotech SA-製薬・医療分野:企業M&A・提携分析
    Summary Calypso Biotech SA (Calypso) is a biopharmaceutical company that develops antibody therapies. The company’s pipeline products include CALY-0001 and CALY-0002. Its CALY-0001 therapeutic antibody is used in the treatment of Crohn’s disease; and CALY-0002 a humanized monoclonal antibody used in …
  • Dixons Carphone plc:企業のM&A・事業提携・投資動向
    Dixons Carphone plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dixons Carphone plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • TPG Telecom Ltd (TPM):企業の財務・戦略的SWOT分析
    TPG Telecom Ltd (TPM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PolyPid Ltd-医療機器分野:企業M&A・提携分析
    Summary PolyPid Ltd (PolyPid) is a clinical stage pharmaceutical company that develops, manufactures and commercialize drugs for extended release and local delivery. The company develops its products using PLEX (Polymer-Lipid Encapsulation MatriX) platform, which helps in products. PolyPid’s pipelin …
  • DiamondRock Hospitality Co:戦略・SWOT・企業財務分析
    DiamondRock Hospitality Co - Strategy, SWOT and Corporate Finance Report Summary DiamondRock Hospitality Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Hyundai Engineering & Construction Co Ltd (000720):企業の財務・戦略的SWOT分析
    Hyundai Engineering & Construction Co Ltd (000720) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Quest Diagnostics Inc (DGX)-医療機器分野:企業M&A・提携分析
    Summary Quest Diagnostics Inc (Quest Diagnostics) is a provider of diagnostic information services to patients and physicians through a chain of laboratories and company-owned patient service centers. It offers comprehensive range of services including clinical testing with gene-based and other esot …
  • Kering SA (KER):企業の財務・戦略的SWOT分析
    Kering SA (KER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Enea AB (ENEA):企業の財務・戦略的SWOT分析
    Summary Enea AB (Enea) is a technology company that provides software products, services and solutions. The company’s product portfolio consists of NFV virtualization platforms, operating systems, device and network management, traffic intelligence, 5g data management, access management and policy c …
  • The Mauritius Commercial Bank Limited
    The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report Summary The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Insulet Corp (PODD):製薬・医療:M&Aディール及び事業提携情報
    Summary Insulet Corp (Insulet) is a medical device company that develops, manufactures and distributes insulin management systems for diabetic patients. Its OmniPod insulin management system is a continuous insulin delivery system for insulin dependent diabetic s. Omnipod system consists of a dispos …
  • MimiVax LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary MimiVax LLC (MimiVax) is a pharmaceutical company that discovers and develops immunotherapeutic vaccines and targeted therapies for the treatment of cancer. The company’s lead candidate is SurVaxM. Its SurVaxM is a cancer vaccine that stimulates a potent immune response and the survivin mole …
  • Corus Entertainment Inc. (CJR.B):企業の財務・戦略的SWOT分析
    Corus Entertainment Inc. (CJR.B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Cosmo Bio Co Ltd (3386):企業の財務・戦略的SWOT分析
    Summary Cosmo Bio Co Ltd (Cosmo Bio) operates as a medical device company that offers markets research reagents and research instruments. The company’s product categories include antibodies, assay and detection, cells and cell culture, bioactive substances, protein engineering, separation and purifi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆